| Cash flow (USD) | Q2 2026 ended Jun 28, 2026 | Q1 2026 ended Mar 29, 2026 | Q4 2025 ended Dec 31, 2025 | Q3 2025 ended Sep 28, 2025 | Q2 2025 ended Jun 29, 2025 | Q1 2025 ended Mar 30, 2025 | Q4 2024 ended Dec 31, 2024 | Q3 2024 ended Sep 29, 2024 |
|---|---|---|---|---|---|---|---|---|
| Net income | -248.00M | 2.69B | -1.65B | 3.54B | 2.91B | 2.97B | 410.00M | 4.46B |
| Depreciation and amortization | 1.62B | 1.61B | 1.69B | 1.66B | 1.63B | 1.62B | 1.79B | 1.75B |
| Stock-based compensation | 249.00M | 272.00M | 225.00M | 201.00M | 203.00M | 170.00M | 177.00M | 274.00M |
| Cash from operations | 835.00M | 2.62B | 5.35B | 4.60B | -582.00M | 2.33B | 6.72B | 6.71B |
| Capital expenditure | -533.00M | -436.00M | -845.00M | -602.00M | -618.00M | -564.00M | -917.00M | -651.00M |
| Free cash flow | 302.00M | 2.18B | 4.50B | 4.00B | -1.20B | 1.77B | 5.80B | 6.06B |
| Acquisitions | 0 | 0 | ||||||
| Cash from investing | 2.11B | 785.00M | -6.15B | -2.43B | 3.95B | 3.27B | -1.62B | -2.06B |
| Net debt issued | 2.98B | 0 | -3.75B | 0 | 0 | 0 | ||
| Cash from financing | -3.66B | -2.86B | 596.00M | -2.48B | -3.20B | -5.23B | -5.11B | -4.64B |
| Net change in cash | -727.00M | 563.00M | -196.00M | -301.00M | 213.00M | 375.00M | -45.00M | 29.00M |
From Pfizer's 10-K and 10-Q filings with the SEC. Fourth quarters, and quarters where the company only reported year-to-date totals, are worked out by subtracting the earlier quarters. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read cash flow or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.